Drug Trial Radar · NCT07107178
A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Aug 8, 2025
Primary completion
May 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Biotroy TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Peking University Cancer Hospital and Institute
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.
Conditions
- Advanced Melanoma
- Advanced Solid Tumor
Interventions
BT02Drug
monoclonal antibody injection with intravenous administration every 2 or 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Through the study completion, an average of 2 years
- Dose limited toxicity(DLT)Time frame: Through the dose escalation phase, an average of 8 months
- Maximum tolerable dose(MTD)Time frame: Through the dose escalation phase, an average of 8 months
- Recommended phase 2 dose(RP2D)Time frame: Through the study completion, an average of 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.